✦ LIBER ✦

A Phase 2 study of migalastat hydrochloride in females with Fabry disease: Selection of population, safety and pharmacodynamic effects

✍ Scribed by Giugliani, R.; Waldek, S.; Germain, D.P.; Nicholls, K.; Bichet, D.G.; Simosky, J.K.; Bragat, A.C.; Castelli, J.P.; Benjamin, E.R.; Boudes, P.F.

Book ID: 123139148
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 268 KB
Volume: 109
Category: Article
ISSN: 1096-7192
DOI: 10.1016/j.ymgme.2013.01.009

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase 2a study to investigate the effe

A phase 2a study to investigate the effect of a single dose of migalastat HCl, a pharmacological chaperone, on agalsidase activity in subjects with Fabry disease

✍ Warnock, David; Bichet, Daniel; Holida, Myrl; Goker-Alpan, Ozlem; Nicholls, Kath 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 96 KB

Safety and pharmacodynamic effects of a

Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies

✍ Dominique P Germain, Roberto Giugliani, Derralynn A Hughes, Atul Mehta, Kathy Ni 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 307 KB

A Phase 1/2 Clinical Trial of Enzyme Rep

A Phase 1/2 Clinical Trial of Enzyme Replacement in Fabry Disease: Pharmacokinetic, Substrate Clearance, and Safety Studies

✍ Christine M. Eng; Maryam Banikazemi; Ronald E. Gordon; Martin Goldman; Robert Ph 📂 Article 📅 2001 🏛 American Society of Human Genetics 🌐 English ⚖ 1000 KB

385 POSTER A phase I safety, pharmacokin

385 POSTER A phase I safety, pharmacokinetic and pharmacodynamic study of carfilzomib, a selective proteasome inhibitor, in subjects with advanced solid tumours

✍ K.P. Papadopoulos; J.R. Infante; A.F. Wong; L.A. Kunkel; A. Patnaik; M. Goldston 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 62 KB

A double-blind, randomized, placebo-cont

A double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety and pharmacodynamics of AT1001 in patients with Fabry disease and AT1001-responsive GLA mutations

✍ Mathews Adera; Chemise Overton; Pol Boudes 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 73 KB

O2-05-08: A phase III study of the effic

O2-05-08: A phase III study of the efficacy, safety and disease modification effect of tramiprosate in mild-to-moderate Alzheimer’s disease

✍ Paul Aisen; Serge Gauthier; Richard Briand; Daniel Saumier; Graziella Soulban; D 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 47 KB